Enzalutamide [40 mg tablet] for first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 23 November 2022)
As final recommendation, the HTA Council does not recommend enzalutamide [40 mg tablet] for first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) for government financing and inclusion in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should enzalutamide [40 mg tablet] for first-line or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC) be funded by the government?
- Secretary of Health Decision: Approved as of 06 December 2022
Evidence and Relevant Documents